FTSE MIB
33.672,01 +39,30 (+0,12%) Dow Jones
37.753,31 -45,66 (-0,12%) Nasdaq
15.683,37 -181,88 (-1,15%) Nikkei 225
38.079,70 +117,90 (+0,31%) Petrolio
82,27 -0,42 (-0,51%) Bitcoin EUR
58.028,90 -589,25 (-1,01%)
Burning Rock Biotech Limited (BNR)
| Chiusura precedente | 0,8400 |
| Aperto | 0,7862 |
| Denaro | 0,5460 x 200 |
| Lettera | 1,0300 x 200 |
| Min-Max giorno | 0,7862 - 0,8000 |
| Intervallo di 52 settimane | 0,5720 - 3,2500 |
| Volume | |
| Media Volume | 49.922 |
| Capitalizzazione | 82,14M |
| Beta (5 anni mensile) | 0,23 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,9600 |
| Prossima data utili | 28 mag 2024 - 03 giu 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 3,95 |
GlobeNewswireBurning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test
GUANGZHOU, China, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for its OverC™ Multi-Cancer Detection Blood Test (MCDBT) in January 2023, its OverC™ MCDBT has been granted Breakthrough Device Designation by the China National Medical Products Administration(NMPA), which represents the only
- GlobeNewswire
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell
GUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal Residual Disease (MRD) product, CanCatch® (PROPHETTM panel), was enrolled in a prospective observational study (MEDAL, MEthylation based Dynamic Analysis for Lung cancer, NCT03634826). The MEDAL is a 5-year study that aimed to investigate the clinical utility of MRD in patients with non-small cell lung
- GlobeNewswire
Burning Rock Reports Second Quarter 2023 Financial Results
GUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2023. Recent Business Updates Therapy Selection and Minimal Residual Disease (MRD) Presented study results on extensive-stage small-cell lung cancer and ovarian cancer a
